Research and Markets: Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/223fca/strategic_overview) has
announced the addition of Decision Resources, Inc.'s new report "Strategic
Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets" to
their offering.

Around the world, the market success of branded drugs is influenced by changes
in healthcare systems and the growing role of payers - and at this point in
time, economic concerns are prompting waves of change, and payers are
increasingly balking at healthcare costs and seeking ways to contain
expenditures. While the major-market healthcare authorities have
cost-consciousness in common, they are deploying various reforms and policies in
different ways in pursuit of that goal. Understanding international trends and
market-specific measures will position biopharma players to operate optimally in
a host of distinct national environments.

Questions Answered in This Report

* In November 2008, the U.S. presidential elections yielded a new Democratic
administration and Congress. What are the healthcare goals of the new
administration? What progress has been made thus far? What are the implications
for the biopharmaceutical industry?
* Also in November 2008, the U.K. Department of Health announced a series of key
reforms. How will drug prices be affected? What are the newest NICE-related
adjustments?
* Use of lower priced generics is a well-established cost-containment measure.
How great is the presence of generics in each major market? How are countries
prompting increased use of generics? When and how will generic versions of
biologics (biosimilars) affect the sales of branded pharmaceuticals?
* In a cost-conscious environment, drug prices are under scrutiny. What are the
key pricing trends in the major markets? How are prices set and adjusted in each
market? What strategies are healthcare authorities and pharma companies using in
their pricing negotiations?

Scope

* Major markets: United States, France, Germany, Italy, Spain, United Kingdom,
Japan.
* Infrastructure: health system organization, funding sources, reform trends.
* Drug pricing and reimbursement: price-setting policies, price control
measures, prices by major market, prices by drug type, outpatient drug pricing
approaches, hospital drug approaches.
* Cost-control measures: biosimilars, dereimbursement, generics, flexible
pricing contracts, formularies, health technology assessment, importation,
incentive programs, multitier formularies, parallel imports, patient copayment
and coinsurance, prescribing budgets, price controls, prior authorization,
quantity limits, reference pricing, step therapy, therapeutic substitution.
* International trends: health technology assessment, generics and biosimilars,
specialty pharmaceuticals, flexible pricing arrangements, evidence of
innovation.

Key Topics Covered:

Executive Summary

1. Introduction

2. United States

3. France

4. Germany

5. Italy

6. Spain

7. United Kingdom

8. Japan

For more information visit
http://www.researchandmarkets.com/research/223fca/strategic_overview

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009